Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens

2002/01/01 by Eilon Barnea, Ilan Beer, R. Patoka +7 · 92 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Antigen #Biology #Computational biology #Context (archaeology) #Epitope #Human leukocyte antigen #Immune system #Immunology #Immunotherapy #Immunotherapy and Immune Responses #MHC class I #MUC1 #Major histocompatibility complex #Molecular biology #T-cell and B-cell Immunology #vaccines and immunoinformatics approaches

paper · pdf · doi:10.1002/1521-4141(200201)32:1<213::aid-immu213>3.0.co;2-8

published in European Journal of Immunology 32(1), 213-222 (Wiley)

openalex publication_date 2002/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Abstract

The Human MHC Project aims at comprehensive cataloging of peptides presented within the context of different human leukocyte antigens (HLA) expressed by cells of various tissue origins, both in health and in disease. Of major interest are peptides presented on cancer cells, which include peptides derived from tumor antigens that are of interest for immunotherapy. Here, HLA-restricted tumor-specific antigens were identified by transfecting human breast, ovarian and prostate tumor cell lines with truncated genes of HLA-A2 and HLA-B7. Soluble HLA secreted by these cell lines were purified by affinity chromatography and analyzed by nano-capillary electrospray ionization-tandem mass spectrometry. Typically, a large peptide pool was recovered and sequenced including peptides derived from MAGE-B2 and mucin and other new tumor-derived antigens that may serve as potential candidates for immunotherapy.

Cited by

• MAGE-B2 autoantibody: a new biomarker for pediatric systemic lupus erythematosus. [europepmc]
• Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. [europepmc]
• An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. [europepmc]
• Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. [europepmc]
• Specific increase in potency via structure-based design of a TCR. [europepmc]
• Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8(+) T Lymphocytes. [europepmc]
• MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. [europepmc]
• Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens. [europepmc]
• Predicting Antigen Presentation-What Could We Learn From a Million Peptides? [europepmc]
• Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression. [europepmc]
• TCR Fingerprinting and Off-Target Peptide Identification. [europepmc]
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. [europepmc]
• Emerging roles of the MAGE protein family in stress response pathways. [europepmc]
• The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design. [europepmc]
• Peptide-based therapeutic cancer vaccine: Current trends in clinical application. [europepmc]
• ARTEMIS: A Novel Mass-Spec Platform for HLA-Restricted Self and Disease-Associated Peptide Discovery. [europepmc]
• Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. [europepmc]
• Potential association factors for developing effective peptide-based cancer vaccines. [europepmc]
• Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome. [europepmc]
• Innovative CRISPR/Cas9-Based Strategy for Allele-Specific HLA Peptidome Analysis Using a Pan-HLA Antibody. [europepmc]
• Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety [europepmc]

Related

• MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
• Direct Detection and Quantification of Neoantigens
• Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-β2m fusion molecules
• Composition of the HLA‐DR‐associated human thymus peptidome
• Targeting peptide antigens using a multiallelic MHC I-binding system